Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: Long-term effects

Therapeutic Apheresis and Dialysis

Volumn 10, Issue 1, 2006, Pages 59-64

  Hashiba, Hirotake ^a,b   Aizawa, Sumio ^c   Tamura, Kazuhiro ^a   Kogo, Hiroshi ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b GERIATRICS RESEARCH INSTITUTE AND HOSPITAL   (Japan)

^c Nakano Ekota Hospital   (Japan)

Author keywords

Aortic calcification; Bisphosphonate; Etidronate; Hemodialysis patient

Indexed keywords

ETIDRONIC ACID;

ADULT; AGED; ARTERY CALCIFICATION; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; EVALUATION; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AORTIC DISEASES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCINOSIS; DISEASE PROGRESSION; ETIDRONIC ACID; FEMALE; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 33644976271     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2006.00345.x     Document Type: Article

References (16)

1. Pohle K Maffert R Ropers D et al. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors Circulation 2001 104 1927 32
2. Davies MR Hruska KA. Pathophysiological mechanisms of vascular calcification in end-stage renal disease Kidney Int 2001 60 472 9
3. London GM Guerin AP Marchais SJ Metivier F Pannier B Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality Nephrol Dial Transplant 2003 18 1731 40
4. Rodan GA. Mechanisms of action of bisphosphonates Annu Rev Pharmacol Toxicol 1998 38 375 88
5. Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease Drugs 1991 42 919 44
6. Hashiba H Aizawa S Tamura K Shigematsu T Kogo H. Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients Ther Apher Dial 2004 8 241 7
7. Matsumoto C Kushida K Yamazaki K Imose K Inoue T. Metacarpal bones mass in normal and osteoporotic Japanese women using computed X-ray densitometry Calcif Tissue Int 1994 55 324 9
8. Jono S Nishizawa Y Shioi A Morii H. Parathyroid hormone-related peptide as a local regulator of vascular calcification. Its inhibitory action on in vitro calcification by bovine vascular smooth muscle cells Arterioscler Thromb Vasc Biol 1997 17 1135 42
9. Shao JS Cheng SL Charlton-Kachigian N Loewy AP. Towler DA. Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice J Biol Chem 2003 278 50195 202
10. Block GA Hulbert-Shearon TE Levin NW Port FK. Association of serum phosphorus and calcium phosphate product with mortality risk in chronic hemodialysis patients: a national study Am J Kidney Dis 1998 31 607 17
11. Cozzolino M Dusso AS Slatopolsky E. Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure J Am Soc Nephrol 2001 12 2511 16
12. Jono S McKee MD Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification Circ Res 2000 87 e10 e17
13. Giachelli CM Jono S Shioi A Nishizawa Y Mori K Morii H. Vascular calcification and inorganic phosphate Am J Kidney Dis 2001 38 S34 7
14. Rosenblum IY Flora L Eisenstein R. The effect of disodium ethane-1-hydroxy- 1,1-diphosphonate (EHDP) on a rabbit model of athero-arteriosclerosis Atherosclerosis 1975 22 411 24
15. Koshiyama H Nakamura Y Tanaka S Minamikawa J. Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes J Clin Endocrinol Metab 2000 85 2793 6
16. Ylitalo R Monkkonen J Yla-Herttuala S. Effects of liposome-encapsulated bisphosphonates on acetylated LDL metabolism, lipid accumulation and viability of phagocyting cells Life Sci 1998 62 413 22